Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) has provided an update.
Alligator Bioscience has reported the preliminary outcome of its recently completed rights issue of units, indicating a subscription level of approximately 64.8 percent, of which 61.2 percent came through the exercise of unit rights and 3.6 percent without rights. As a result, guarantee commitments will be utilized for about 9.1 percent of the offering, and the company expects to raise roughly SEK 91 million before issue costs and debt repayments, including bridge loans and part of an outstanding loan to Fenja Capital II A/S. The rights issue, which comprised up to 306.7 million units—each consisting of two ordinary shares and one warrant—closed on 18 December 2025, with the final outcome scheduled to be announced on 22 December 2025, providing Alligator with important capital to support its ongoing operations and clinical pipeline.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company focused on developing clinical-stage, tumor-directed antibody drugs targeting the CD40 receptor, a validated immuno-oncology approach aimed at priming T cells and reversing tumor-induced immunosuppression. Its lead candidate, mitazalimab, is ready for Phase 3 development and has shown strong 24‑month survival data in metastatic pancreatic cancer, positioning the company within the oncology segment of the biotech market. Alligator is listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.
Average Trading Volume: 4,570,260
Technical Sentiment Signal: Sell
Current Market Cap: SEK212.2M
See more data about ATORX stock on TipRanks’ Stock Analysis page.